Professional
Added to YB: 2024-02-26
Pitch date: 2024-02-25
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
+7.06%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$425.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
growth
Show full summary:
Aristotle Capital Core Equity New Position - Vertex Pharmaceuticals
VRTX: CF drug leader w/ 4 on market. Pipeline: more CF, sickle cell, thalassemia, AAT deficiency, pain. Late-stage pain studies to fuel growth. Trades below 5yr avg w/ $12.5B net cash. Compelling value.
Read full article (1 min)